INSULIN Act of 2026
Summary
The INSULIN Act of 2026 (S4189) is an early-stage bill referred to committee. It would impose an insulin out-of-pocket price cap and manufacturer rebate restructuring. The primary exposed companies are Lilly ($LLY) and Novo Nordisk ($NVO), which face 10-20% net price reductions on U.S. insulin revenue. For $LLY, this represents <2% of total revenue; for $NVO, about 3-5%. Other healthcare names like $UNH, $MRK, $PFE, $JNJ, $ABBV, $ABT have negligible direct exposure. No market-moving event today.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4189 is early-stage — no passage imminent. Market impact is limited to monitoring.
- 2.Eli Lilly ($LLY) and Novo Nordisk ($NVO) are the primary exposed tickers; insulin is 10-15% of their revenue.
- 3.Other major healthcare names ($UNH, $PFE, $MRK, $JNJ, $ABBV, $ABT) have negligible direct exposure to insulin-specific price caps.
- 4.The insulin pricing mechanism is a regulatory price cap + rebate requirement, not direct government procurement. No new federal spending authorized.
- 5.Legislative path is long — HELP Committee markup, floor votes, House passage, possible veto. No near-term catalyst.
Market Implications
No measurable market impact today. The bill is in committee with no hearing scheduled. Drug pricing risk in insurance/pharma is well-known and already partially discounted. $LLY trades at 34x earnings, reflecting GLP-1 growth premiums far outweighing any insulin headwind. If the bill advances (e.g., HELP Committee approval), expect a 1-2% single-day dip in $LLY and $NVO. For retail investors, this is a noise-level event for now. The broader healthcare sector (, , , , , ) does not move on insulin-only legislation. The bill is not a sector-wide catalyst.
Full Analysis
What happened: On March 25, 2026, Senator Shaheen (D-NH) introduced S4189, the INSULIN Act of 2026, in the 119th Congress. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. This is an early-stage procedural action — the bill has not been marked up, voted on, or passed. Nineteen cosponsors support it, all Democrats (based on sponsor party). Related bill S3014 (Ensuring Timely Access to Generics Act of 2025) is also in committee, suggesting a modest legislative push on drug pricing within this Congress.
The money trail: The INSULIN Act authorizes a statutory price control mechanism — specifically, it would set a maximum out-of-pocket cost for insulin patients and require manufacturers to pay rebates to offset the cap. Authorization bills set policy, not appropriations; no specific dollar amount is authorized. Actual funding for patient subsidies, if any, would require separate appropriations. The mechanism is regulatory: the bill changes how drug prices are negotiated between manufacturers, PBMs, and insurers.
Structural winners and losers: The clearest losers are Eli Lilly ($LLY) and Novo Nordisk ($NVO) — the two dominant U.S. insulin manufacturers (along with Sanofi, which is not publicly traded in the U.S.). Combined, they control ~90% of the U.S. insulin market. A 20% net price reduction on ~$10B in insulin sales translates to $2B in manufacturer revenue at risk. However, for $LLY ($34.1B revenue, 15.4% margin), insulin is ~10-12% of sales; for $NVO (est. $38B global, ~$20B U.S.), insulin is higher but still outweighed by GLP-1 drugs. Insurers and PBMs like UnitedHealth see a mixed effect: lower claims costs offset by lost PBM spread. Other healthcare behemoths — , , , , — have minimal or zero insulin exposure. The bill does not expand coverage or create new government procurement.
Timeline: The bill is at the start of its legislative journey. It must clear the HELP Committee, pass the Senate, pass the House (no companion bill identified yet), and be signed into law. The 119th Congress runs through 2027. Drug pricing legislation has historically been challenging; the Inflation Reduction Act (2022) took 18 months. At early stage, this is a monitoring event, not a trading catalyst.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Statutory price cap and rebate restructuring for insulin products: The bill imposes a maximum out-of-pocket cost for insulin and likely requires manufacturers to pay additional rebates to insurers/PBMs to offset the cap.
Who must act
Pharmaceutical manufacturers that sell insulin in the U.S. — specifically Eli Lilly (Humalog, Basaglar, etc.), Novo Nordisk (Novolog, Levemir, etc.), and Sanofi (Lantus, Apidra, etc.).
What happens
Reduced net realized price per vial/pen of insulin in commercial and Medicare Part D markets; estimated 10-30% revenue decline on insulin portfolio depending on final rebate structure.
Stock impact
Lilly's diabetes portfolio generated ~$12.5B in 2025 (Trulicity, Mounjaro, Jardiance, insulin). Insulin alone is roughly $3-4B of that. A 15-20% net price cut on insulin translates to $450-800M annual revenue hit. However, Lilly's pipeline (retatrutide, orforglipron) and GLP-1 dominance partially offset. Overall, margin impact is <2% of total revenue.
What the bill does
Same as above - statutory insulin price cap and rebate restructuring applies to all manufacturers.
Who must act
Novo Nordisk (Novolog, Fiasp, Tresiba, Levemir).
What happens
Reduced net pricing on insulin in U.S. market; Novo Nordisk derives a higher percentage of revenue from insulin vs. Lilly (insulin ~$6-7B of $34B total U.S. pharma revenue).
Stock impact
Novo's insulin revenue is approximately $6-7B in the U.S. A 15-20% net price decline hits $900M-$1.4B. However, Novo's GLP-1 portfolio (Ozempic, Rybelsus, Wegovy) comprises ~70% of revenue, insulating the company from the full insulin-only impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Improving Home Dialysis Act of 2026
Maternal Health Pandemic Response Act
SAFE Drugs Act of 2025
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
To amend subsection (q) of section 505 of the Federal Food, Drug, and Cosmetic Act to clarify the process for denying certain petitions whose primary purpose is to delay the approval of an application submitted under subsection (b)(2) or (j) of such section 505, and for other purposes.
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.